Previous 10 | Next 10 |
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
ProQR Therapeutics (NASDAQ:PRQR) -69% after the trial for sepofarsen in Leber congenital amaurosis did not meet main goal. Betterware de Mexico (NASDAQ:BWMX) -26% on Q4 earnings release. Hudson Capital (NASDAQ:HUSN) -13%. PetVivo Holdings (NASDAQ:PETV) -18% on...
ProQR Therapeutics (NASDAQ:PRQR) announced on Friday that the company’s pivotal Phase 2/3 Illuminate trial for RNA therapy sepofarsen in EP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet the primary endpoint of Best Corrected Visual Acuity (BCVA). ProQR (PRQR) is curren...
Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus sham Additional analyses to be conducted and presented at a future medical congress Sepofarsen continues to be generally well tolerated Strong cash p...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
AMC Entertainment Holdings (NYSE:AMC) +14% as preliminary Q4 revenue tops consensus. Wallbox (NYSE:WBX) +14% Uber and Wallbox to expand partnership to all of the U.S. Spire Global (NYSE:SPIR) +10% as preliminary Q4 revenue soars 111% Y/Y. ObsEva (NASDAQ:OBSV) +9%. ProQR Th...
Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has ...
ProQR Therapeutics (NASDAQ:PRQR) announces that the first patient has been dosed in Phase 2/3 Sirius and Celeste clinical trials of RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome. RP and Usher syndrome associated with USH2A are inherited retina...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...